NHS
Bolton
NHS Foundation Trust

FREEDOM OF INFORMATION

REF: 2026-94
Subject: Treatment of Waldenström Macroglobulinaemia (WM) & Marginal Zone Lymphoma (MZL)

Dear Sir/Madam,

Thank you for your email dated **30/01/2026** where you requested information about **Treatment of Waldenström Macroglobulinaemia (WM) & Marginal Zone Lymphoma (MZL).**

The information you requested is enclosed.

Question	Answer
1. Does your Trust treat patients for the two following conditions? Yes/No **Waldenström macroglobulinaemia (WM) (ICD-10 C88.0)** **Marginal zone lymphoma (MZL) (ICD-10 C83.0 & C88.4)**	Yes
If yes: 1a. How many patients did the Trust treat in calendar year 2025 (January to December) for each of the below conditions? **Waldenström macroglobulinaemia (WM) Marginal zone lymphoma (MZL**	Waldenström macroglobulinaemia (WM) <5 patients treated at Bolton NHS FT Marginal zone lymphoma (MZL) <5 patients treated at Bolton NHS FT
1b. Are there any ongoing clinical trials running at the Trust for each of the below conditions? Please can you advise on any details available on the clinical trials. **Waldenström macroglobulinaemia (WM)** **Marginal zone lymphoma (MZL)**	We have no clinical trials.
Please skip 1c to question 2 and 3. If no: 1c. Which Trust(s) does the Trust refer patients onto for treatment for each of the above conditions?	N/A

Thank you for answering this survey.

2. How many patients (and new patients* if possible) received treatment for Waldenström macroglobulinaemia (WM) in the period 1st July 2025 to 31st December 2025?

Waldenström macroglobulinaemia (WM) (ICD-10 C88.0)		
Regimen	**Total Patients**	**New Patients***
Fludarabine, cyclophosphamide and rituximab (Known as FCR)	0	0
Bendamustine in combination with rituximab (Known as BR)	0	0
Ibrutinib	0	0
Ibrutinib in combination with rituximab	0	0
Zanubrutinib	0	0
Acalabrutinib	0	0
Chemotherapy (Other than the listed regimens)	<5	<5
Wait and watch - no active treatment and monitoring only	<5	<5
Any other treatment (Other than the listed regimens)	0	0

***Please define a new patient as a new patient to treatment, receiving the specified treatment for the first time since December 2024.**

3. How many patients (and new patients* if possible) received treatment for Marginal zone lymphoma (MZL) in the period 1st July 2025 to 31st December 2025?

Marginal zone lymphoma (MZL) (ICD-10 C83.0 & C88.4)		
Regimen	**Total Patients**	**New Patients***
Bendamustine in combination with rituximab (Known as BR)	0	0
Chlorambucil in combination with rituximab (Known as CR)	0	0
R CVP (Rituximab + cyclophosphamide + vincristine + prednisolone)	0	0
R CHOP (Rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone)	0	0

Zanubrutinib	0	0
Stem Cell Transplant	0	0
Wait and watch - no active treatment and monitoring only	<5	<5
Any other treatment (Other than the listed regimens)	<5	<5

***Please define a new patient as a new patient to treatment, receiving the specified treatment for the first time since December 2024.**

If you have any queries or concerns please do not hesitate to contact the Freedom of Information Department. It would be helpful to quote the above reference number in any future communication.

If you are unhappy with the service you have received in relation to your request and wish to make a complaint or request a review of our decision, you should write to The Chief Executive, Bolton NHS Foundation Trust, The Royal Bolton Hospital, Minerva Road, Farnworth, Bolton. BL4 0JR.

If you are not content with the outcome of your complaint you may apply directly to the Information Commissioner. Generally the Information Commissioner cannot make a decision unless you have exhausted the complaints procedure provided by Bolton NHS Foundation Trust. The Information Commissioner can be contacted at The Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire. SK9 5AF.

The information supplied to you continues to be protected by the Copyright Design and Patents Act 1998. You are free to use it for your own purposes, including any non-commercial research you are doing and for the purposes of news reporting. Any other reuse, for example commercial publication requires the permission of the Trust. You must ensure you gain the Trust permission before reproducing any third party information.

Yours sincerely,

Information Governance Department

Bolton NHS Foundation Trust
01204 390861
FOI@boltonft.nhs.uk
Informatics Building | Opposite N Block | Royal Bolton Hospital

NHS
Bolton
NHS Foundation Trust

Improving care,
transforming lives...for a better Bolton

Improving care,
transforming lives...for a better Bolton